NCT02735707(1010. ClinicalTrials.gov. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). Bethesda: National Library of Medicine; 2016 [cited 2020 Oct 28]. [First posted Apr 13, 2016; Last update posted Oct 12, 2020]. Available from: https://ClinicalTrials.gov/show/NCT02735707 https://ClinicalTrials.gov/show/NCT02735...
)
|
IV |
Doença respiratória aguda grave e pneumonia adquirida na comunidade grave |
Corticosteroides versus antibióticos versus macrolídeo versus antiviral para gripe versus LPV/Rit versus HCQ versus IFN-β1a versus Anak versus Tmab versus Smab versus Vit C versus heparina versus sinvastatina versus PC versus TP |
1 ou 2 unidades em 48 horas |
>18 |
11/4/2016 |
1/12/2023 |
58 |
Recrutamento |
NCT04391101(1111. ClinicalTrials.gov. Convalescent plasma for patients with COVID-19: a pilot study. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 2, 2020; Last update posted Aug 17, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04332380 https://ClinicalTrials.gov/show/NCT04332...
)
|
III |
Pacientes graves tratados na UTI |
PC associado a TP versus TP |
400-500mL |
>18 |
1/6/2020 |
1/12/2021 |
19,2 |
Ainda sem recrutamento |
NCT04372979(1212. ClinicalTrials.gov. Efficacy of convalescent plasma therapy in the early care of COVID-19 patients (PLASCOSSA). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 4, 2020; Last update posted Oct 26, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04372979 https://ClinicalTrials.gov/show/NCT04372...
)
|
III |
Atendimento precoce de pacientes hospitalizados |
PC associado a TP versus PP associado a TP |
200-230mL |
18-80 |
1/5/2020 |
1/5/2021 |
37,3 |
Ainda sem recrutamento |
NCT04418518(1313. ClinicalTrials.gov. A trial of CONvalescent plasma for hospitalized adults with acute COVID-19 respiratory illness (CONCOR-1). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted June 5, 2020; Last update posted July 7, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04418518 https://ClinicalTrials.gov/show/NCT04418...
)
|
III |
Atendimento precoce a pacientes hospitalizados |
PC associado a TP versus TP |
500mL de doador único ou 2 unidades de 250mL de 1-2 doações |
18-70 |
24/6/2020 |
1/12/2021 |
15,6 |
Recrutamento |
NCT04355767(1414. ClinicalTrials.gov. Convalescent plasma in outpatients with COVID-19 (C3PO). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 21, 2020; Last update posted Sep 29, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04355767 https://ClinicalTrials.gov/show/NCT04355...
)
|
III |
Pacientes graves/críticos hospitalizados |
PC (títulos de anticorpos ≥1:160) versus placebo |
PC: 1 unidade versus placebo: solução fisiológica com multivitamínico |
>18 |
11/8/2020 |
1/12/2022 |
4,0 |
Ainda sem recrutamento |
NCT04432103(1515. ClinicalTrials.gov. Treatment of severe and critical COVID-19 pneumonia with convalescent plasma. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted June 16, 2020; Last update posted June 17, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04432103 https://ClinicalTrials.gov/show/NCT04432...
)
|
III |
Pacientes graves/críticos hospitalizados |
PC de IgG (pacientes graves versus pacientes críticos) associado a TP |
NR |
>19 |
19/6/2020 |
30/9/2020 |
84,5 |
Ainda sem recrutamento |
NCT04348656(1616. ClinicalTrials.gov. CONvalescent plasma for hospitalized adults with COVID-19 respiratory illness (CONCOR-1). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 16, 2020; Last update posted Oct 20, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04348656 https://ClinicalTrials.gov/show/NCT04348...
)
|
III |
Atendimento precoce a pacientes hospitalizados |
PC versus TP |
500mL de doador único ou 2 unidades de 250mL de 1-2 doações |
>20 |
14/5/2020 |
31/12/2020 |
53,2 |
Recrutando |
NCT04425915(1717. ClinicalTrials.gov. Efficacy of convalescent plasma therapy in patients with COVID-19. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted June 11, 2020; Last update posted Sep 3, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04425915 https://ClinicalTrials.gov/show/NCT04425...
)
|
III |
Pacientes graves/críticos hospitalizados |
PC associado a TP versus TP |
2 doses de 250mL em dias consecutivos iniciadas no dia 3 do início dos sintomas |
>21 |
14/6/2020 |
30/5/2021 |
26,3 |
Recrutando |
NCT04362176(1818. ClinicalTrials.gov. Passive immunity trial of the nation for COVID-19 (PassItOnII). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 24, 2020; Last update posted Aug 27, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04362176 https://ClinicalTrials.gov/show/NCT04362...
)
|
III |
Pacientes hospitalizados ou em UTI |
Patógeno reduzido PC versus placebo |
PC: 500mL em 12 horas (dia 0) versus placebo: 250mL de Ringer lactato associado a multivitaminas (dia 1) |
>22 |
24/4/2020 |
1/4/2021 |
41,8 |
Recrutando |
NCT04381858(1919. ClinicalTrials.gov. Convalescent plasma vs human immunoglobulin to treat COVID-19 pneumonia. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 11, 2020; Last update posted May 12, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04381858 https://ClinicalTrials.gov/show/NCT04381...
)
|
III |
Insuficiência respiratória grave com ventilação mecânica invasiva |
PC (títulos de anticorpos > 1:164) versus HIg |
PC: 400mL (2 unidades) versus HIg 0,3g/kg/dia (5 doses) |
16-18 |
6/5/2020 |
30/9/2020 |
89,1 |
Recrutando |
NCT04361253(2020. ClinicalTrials.gov. Evaluation of SARS-CoV-2 (COVID-19) antibody-containing plasma therapy (ESCAPE). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 24, 2020; Last update posted May 18, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04361253 https://ClinicalTrials.gov/show/NCT04361...
)
|
III |
Pacientes hospitalizados |
PC (título alto) versus PP (PFC ou PC 24) |
PC-AT 2 doses de 250mL de doador único em 24 horas; PFC: 2 unidades de 200-275mL |
>1 |
30/4/2020 |
1/12/2021 |
23,6 |
Recrutando |
NCT04376034(2121. ClinicalTrials.gov. Convalescent plasma collection and treatment in pediatrics and adults. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 6, 2020; Last update posted May 6, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04376034 https://ClinicalTrials.gov/show/NCT04376...
)
|
III |
Gravidade leve, moderada e grave/crítica |
PC associado a TP versus TP |
Adultos: 200 a 250mL; crianças: 10mL/kg; 2 unidades de pacientes graves ou em condição crítica |
>30 dias |
16/4/2020 |
30/3/2021 |
43,4 |
Recrutando |
NCT04483960(2222. ClinicalTrials.gov. Australasian COVID-19 trial (ASCOT) [Internet]. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted July 23, 2020; Last update posted July 23, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04483960 https://ClinicalTrials.gov/show/NCT04483...
)
|
III |
Sem pacientes graves |
LPV/Rit versus HCQ versus PC |
1 unidade no dia 1 e no dia 2 |
>18 |
21/7/2020 |
12/6/2022 |
8,0 |
Recrutando |
NCT04345289(2323. ClinicalTrials.gov. Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 14, 2020; Last update posted July 31, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04345289 https://ClinicalTrials.gov/show/NCT04345...
)
|
III |
Pacientes hospitalizados com doença leve, moderada e grave/crítica |
PC associado a TP (Smab versus baricitinibe versus HCQ) versus TP associado a placebo injetável |
PC: (2 vezes de 300mL) e dose única de 600mL; placebo: (2 vezes de 300mL) e dose única de 600mL de solução fisiológica IV por placebo: 3 vezes ao dia (7 dias) |
>18 |
1/5/2020 |
15/6/2021 |
33,2 |
Recrutando |
NCT04342182(2424. ClinicalTrials.gov. Convalescent plasma as therapy for Covid-19 severe SARS-CoV-2 disease (CONCOVID Study). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 10, 2020; Last update posted May 18, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04342182 https://ClinicalTrials.gov/show/NCT04342...
)
|
II-III |
Pacientes hospitalizados |
PC associado a TP versus TP |
300mL (de acordo com o protocolo Erasmus MC KIS) |
>18 |
8/4/2020 |
1/7/2020 |
100 |
Recrutando |
NCT04388410(2525. ClinicalTrials.gov. Safety and efficacy of convalescent plasma transfusion for patients with COVID-19 (EPCOvid-1). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 14, 2020; Last update posted Aug 26, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04388410 https://ClinicalTrials.gov/show/NCT04388...
)
|
II-III |
Pacientes hospitalizados com doença grave ou risco de doença grave |
PC versus placebo |
PC: 2 unidades de 200mL dentro de 24-72 horas; placebo: 200mL de soro fisiológico |
>18 |
25/8/2020 |
31/12/2020 |
15,6 |
Ainda sem recrutamento |
NCT04374526(2626. ClinicalTrials.gov. Early transfusIon of convalescent plasma in elderly COVID-19 patients. to prevent disease progression. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 5, 2020; Last update posted Oct 6, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04374526 https://ClinicalTrials.gov/show/NCT04374...
)
|
II-III |
Pacientes hospitalizados |
PC associado a TP versus TP |
200mL/dia por 3 dias |
>65 |
27/5/2020 |
30/6/2021 |
27,6 |
Recrutando |
NCT04384588(2727. ClinicalTrials.gov. COVID19-convalescent plasma for treating patients with active symptomatic COVID 19 infection (FALP-COVID). Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 12, 2020; Last update posted May 12, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04384588 https://ClinicalTrials.gov/show/NCT04384...
)
|
II-III |
Pacientes oncológicos e não oncológicos com doença grave |
PC associado a TP versus TP |
1 ou mais unidades |
>15 |
7/4/2020 |
6/4/2021 |
44,0 |
Recrutando |
NCT04425837(2828. ClinicalTrials.gov. Effectiveness and safety of convalescent plasma in patients with high-risk COVID-19. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted June 11, 2020; Last update posted June 11, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04425837 https://ClinicalTrials.gov/show/NCT04425...
)
|
II-III |
Pacientes hospitalizados com alto risco de doença grave ou em UTI |
PC (títulos de anticorpos ≥1:160) associado a TP versus TP |
2 doses de 200mL por dia |
>18 |
1/7/2020 |
1/2/2021 |
34,9 |
Ainda sem recrutamento |
NCT04395170(2929. ClinicalTrials.gov. Convalescent plasma (PC) and human intravenous anti-COVID-19 immunoglobulin (IV anti COVID-19 IgG) in patients hospitalized for COVID-19. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28] [First posted May 20, 2020; Last update posted July 10, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04395170 https://ClinicalTrials.gov/show/NCT04395...
)
|
II-III |
Atendimento precoce a pacientes hospitalizados |
PC associado a TP versus anti-COVID-19 HIg versus TP |
PC: 200-250mL (dias 1 e 3); Solução IgG a 10%: 50mL (paciente ≥50kg); 1mL/kg (paciente <50Kg), nos dias 1 e 3 |
>18 |
1/9/2020 |
1/6/2021 |
4,8 |
Ainda sem recrutamento |
NCT04380935(3030. ClinicalTrials.gov. Effectiveness and safety of convalescent plasma therapy on COVID-19 patients with acute respiratory distress syndrome. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28] [First posted May 8, 2020; Last update posted Aug 18, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04380935 https://ClinicalTrials.gov/show/NCT04380...
)
|
II-III |
Pacientes hospitalizados na UTI (usando ventilação mecânica) |
PC associado a TP versus TP |
NR |
>18 |
18/5/2020 |
31/10/2020 |
71,7 |
Ainda sem recrutamento |
NCT04332835(3131. ClinicalTrials.gov. Convalescent plasma for patients with COVID-19: a randomized, open label, parallel, controlled clinical study. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted Apr 3, 2020; Last update posted Sep 2, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04332835 https://ClinicalTrials.gov/show/NCT04332...
)
|
II-III |
Gravidade moderada e grave/crítica |
PC associado a TP versus HCQ associado a TP |
250mL nos dias 1 e 2 |
18-60 |
8/8/2020 |
31/10/2020 |
44,0 |
Ainda sem recrutamento |
NCT04385043(3232. ClinicalTrials.gov. Hyperimmune plasma in patients with COVID-19 severe infection. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 12, 2020; Last update posted May 12, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04385043 https://ClinicalTrials.gov/show/NCT04385...
)
|
II-III |
Pacientes graves/críticos hospitalizados |
PC associado a TP versus TP |
NR |
18-60 |
1/5/2020 |
15/5/2021 |
35,9 |
Recrutando |
NCT04381936(3333. ClinicalTrials.gov. Randomised evaluation of COVID-19 therapy. Bethesda: National Library of Medicine; 2020 [cited 2020 Oct 28]. [First posted May 11, 2020; Last update posted Sep 29, 2020]. Available from: https://ClinicalTrials.gov/show/NCT04381936 https://ClinicalTrials.gov/show/NCT04381...
)
|
II-III |
Pacientes hospitalizados com alto risco de doença grave |
LPV/Rit versus corticosteroide versus HCQ versus Azi versus Tmab associado a TP versus PC associado a TP |
275mL±75mL nos dias 1 e 2 |
Todos |
19/3/2020 |
1/12/2031 |
4,2 |
Recrutamento |